Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

5-EPIFAT trial protocol : a multi-center, randomized, placebo-controlled trial of the efficacy of pharmacotherapy for fatigue using methylphenidate, bupropion, ginseng, and amantadine in advanced cancer patients on active treatment

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Publisher Information:
      Linnéuniversitetet, Institutionen för hälso- och vårdvetenskap (HV) Ahvaz Jundishapur Univ Med Sci, Iran Tarbiat Modares Univ, Iran Clayton State Univ, USA Ahvaz Jundishapur Univ Med Sci, Iran IRCCS Osped Sacro Cuore Don Calabria, Italy Tung Wah Coll, China Ahvaz Jundishapur Univ Med Sci, Iran Ahvaz Jundishapur Univ Med Sci, Iran Ahvaz Jundishapur Univ Med Sci, Iran;Deakin Univ, Australia Iran Univ Med Sci, Iran Shahid Sadoughi Univ Med Sci, Iran 2024
    • نبذة مختصرة :
      Background Cancer-related fatigue (CRF) is still undertreated in most patients, as evidence for pharmacologicaltreatments is limited and conflicting. Also, the efficacy of the pharmacological agents relative to each other is stillunclear. Therefore, medications that may potentially contribute to improving CRF will be investigated in this head-toheadtrial. Our main objective is to compare the efficacy of methylphenidate vs. bupropion vs. ginseng vs. amantadinevs. placebo in patients with advanced cancer. Methods The 5-EPIFAT study is a 5-arm, randomized, multi-blind, placebo-controlled, multicenter trial that will usea parallel-group design with an equal allocation ratio comparing the efficacy and safety of four medications (Methylphenidatevs. Bupropion vs. Ginseng vs. Amantadine) versus placebo for management of CRF. We will recruit 255adult patients with advanced cancer who experience fatigue intensity ≥ 4 based on a 0–10 scale. The study periodincludes a 4-week intervention and a 4-week follow-up with repeated measurements over time. The primary outcomeis the cancer-related fatigue level over time, which will be measured by the functional assessment of chronic illnesstherapy-fatigue (FACIT-F) scale. To evaluate safety, the secondary outcome is the symptomatic adverse events, whichwill be assessed using the Patient-Reported Outcomes version of the Common Terminology Criteria for AdverseEvents in cancer clinical trials (PRO-CTCAE). Also, a subgroup analysis based on a decision tree-based machine learningalgorithm will be employed for the clinical prediction of different agents in homogeneous subgroups. Discussion The findings of the 5-EPIFAT trial could be helpful to guide clinical decision-making, personalization treatmentapproach, design of future trials, as well as the development of CRF management guidelines. Trial registration IRCT.ir IRCT20150302021307N6. Registered on 13 May 2023.
    • الموضوع:
      Fatigue; Pharmacological treatment; Protocol; Randomized controlled trial; Study design; Pharmacology and Toxicology; Farmakologi och toxikologi; Cancer and Oncology; Cancer och onkologi; Article in journal; info:eu-repo/semantics/article; text
    • الرقم المعرف:
      10.1186.s13063-024-08078-w
    • Availability:
      Open access content. Open access content
      info:eu-repo/semantics/openAccess
    • Note:
      application/pdf
      English
    • Other Numbers:
      UPE oai:DiVA.org:lnu-129145
      0000-0002-6352-7008
      0000-0002-4257-282X
      doi:10.1186/s13063-024-08078-w
      PMID 38570861
      ISI:001198237600001
      Scopus 2-s2.0-85189612600
      1457291878
    • Contributing Source:
      UPPSALA UNIV LIBR
      From OAIster®, provided by the OCLC Cooperative.
    • الرقم المعرف:
      edsoai.on1457291878
HoldingsOnline